Previous 10 | Next 10 |
Codexis ( CDXS ) -23% as forecast comes below estimates . 10x Genomics ( TXG ) -19% on guiding Q2 revenues below consensus . Innovative Industrial Properties ( IIPR ) -21% . Lantern Pharma ( LTRN ) -10% . Sunrun ( RUN ) -8%...
Lantern Pharma ( NASDAQ: LTRN ) said the U.S. Food and Drug Administration (FDA) cleared the company to proceed with a phase 2 trial of LP-300 for never smoker patients with advanced non-small cell lung cancer (NSCLC). The study, dubbed Harmonic, will include 90 p...
The Harmonic™ trial is a Phase 2 multi-center study focused on never smokers with advanced non-small cell lung cancer (NSCLC) and will begin patient enrollment during Q3 2022. In a previous Phase 3 multi-center clinical trial, a subset of never smoker patients with NSCLC re...
Lantern Pharma to Host Virtual KOL Event on Glioblastoma Multiforme (GBM) with Collaborators from Johns Hopkins during Brain Tumor Awareness Month PR Newswire DALLAS , May 12, 2022 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN ), a clinical st...
Lantern Pharma Inc. (NASDAQ: LTRN ), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("A.I.") and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today a...
The following slide deck was published by Lantern Pharma Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Lantern Pharma Inc. 2022 Q1 - Results - Earnings Call Presentation
Lantern Pharma Inc. (LTRN) Q1 2022 Earnings Conference Call May 3, 2022 16:30 ET Company Participants Nicole Leber - Investor Relations Associate, Finance & Administrative Coordinator Panna Sharma - President & Chief Executive Officer David Margrave - Chief Financial Officer & Sec...
Lantern Pharma press release (NASDAQ:LTRN): Q1 GAAP EPS of -$0.38. $65.2 million of cash, cash equivalents and marketable securities as of March 31, 2022 For further details see: Lantern Pharma GAAP EPS of -$0.38
Lantern Pharma Reports First Quarter 2022 Financial Results and Operational Highlights PR Newswire RADR ® , Lantern's proprietary A.I. and machine learning platform, has now surpassed 20 billion data points, enhancing its precision, insights, and capabilities ...
Lantern Pharma's Board of Directors Names Maria Maccecchini, Ph.D. as a Director Nominee to Lantern's Board of Directors PR Newswire DALLAS , April 26, 2022 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN ), a clinical stage biopharmaceutical co...
News, Short Squeeze, Breakout and More Instantly...
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine learning to transform the cost, pace, and timeline of oncology drug discovery and development, today announced a significant advancement towards the development of a diagn...
LP-284 is currently in a Phase 1 clinical trial, having been developed with guidance from Lantern’s AI platform, RADR ® , as a potential therapy for relapsed or refractory non-Hodgkin’s lymphoma and certain genomically defined sarcomas. LP-284 is the third molecule brou...
Active clinical trials across three AI-guided drug candidates with initial data and clinical readouts for LP-184 on-track for the second half of 2024. Obtained regulatory allowance to begin Phase 2 Harmonic™ clinical trial enrollment in Japan and Taiwan where approximately 30-35+% ...